WO2023074707A1 - Aliment améliorant l'obésité - Google Patents
Aliment améliorant l'obésité Download PDFInfo
- Publication number
- WO2023074707A1 WO2023074707A1 PCT/JP2022/039801 JP2022039801W WO2023074707A1 WO 2023074707 A1 WO2023074707 A1 WO 2023074707A1 JP 2022039801 W JP2022039801 W JP 2022039801W WO 2023074707 A1 WO2023074707 A1 WO 2023074707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obesity
- food
- improving
- cannabidiol
- weight
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 142
- 235000013305 food Nutrition 0.000 title claims abstract description 134
- 235000020824 obesity Nutrition 0.000 title claims abstract description 55
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 80
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 79
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 79
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 79
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 24
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 22
- 230000009471 action Effects 0.000 claims description 33
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 26
- 235000001785 ferulic acid Nutrition 0.000 claims description 26
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 26
- 229940114124 ferulic acid Drugs 0.000 claims description 26
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 26
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 26
- 229920001353 Dextrin Polymers 0.000 claims description 23
- 239000004375 Dextrin Substances 0.000 claims description 23
- 235000019425 dextrin Nutrition 0.000 claims description 23
- 229920002472 Starch Polymers 0.000 claims description 18
- 235000019698 starch Nutrition 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 4
- 235000010208 anthocyanin Nutrition 0.000 claims description 4
- 239000004410 anthocyanin Substances 0.000 claims description 4
- 229930002877 anthocyanin Natural products 0.000 claims description 4
- 150000004636 anthocyanins Chemical class 0.000 claims description 4
- 235000005487 catechin Nutrition 0.000 claims description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 4
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 4
- 229940074393 chlorogenic acid Drugs 0.000 claims description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- -1 gummy Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 230000003579 anti-obesity Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000000052 comparative effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 20
- 210000000577 adipose tissue Anatomy 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 17
- 238000012790 confirmation Methods 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 240000004308 marijuana Species 0.000 description 8
- 244000025254 Cannabis sativa Species 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 6
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960004242 dronabinol Drugs 0.000 description 4
- 235000009120 camo Nutrition 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
Definitions
- the present invention relates to food for improving obesity.
- hemp is known as a useful substance for multiple sclerosis, neuropathic pain, cancer, arteriosclerosis, obesity, metabolic syndrome, and diabetes.
- Cannabidiol is a cannabinoid, but unlike tetrahydrocannabinol, which is known as a psychotropic drug, cannabidiol does not cause euphoria or euphoria, and is not abused, dependent, or tolerated. are compounded.
- composition capable of promoting the obesity-improving action of cannabidiol in particular, a composition capable of improving obesity as part of a daily diet by being composed of ingredients that can be incorporated into foods has not yet been proposed. do not have.
- the present invention has been made in view of such circumstances, and provides an obesity-improving food containing a slimming aid composition that promotes the obesity-improving action of cannabidiol.
- the food for improving obesity includes (1) a food for improving obesity containing cannabidiol and a slimming aid composition that promotes the obesity-improving action of the cannabidiol.
- the slimming aid composition is composed of an indigestible polymer compound and polyphenols.
- the food for improving obesity also has the following characteristics.
- the cannabidiol is contained in 100 parts by weight of the food for improving obesity in a proportion of 0.05 to 10 parts by weight.
- the indigestible polymer compound contains at least one selected from dextrin, starch, protein, and dietary fiber.
- the indigestible polymer compound is contained at a ratio of 3 to 50 parts by weight in 100 parts by weight of the food for improving obesity.
- the polyphenols contain at least one selected from anthocyanin, ferulic acid, chlorogenic acid, catechin, and curcumin.
- the polyphenols should be contained at a ratio of 1.5 to 20 parts by weight in 100 parts by weight of the food for improving obesity.
- the dosage form is powder, fine granules, granules, soft capsules, hard capsules, jelly, gummy, liquid or tablet.
- the obesity-improving food contains cannabidiol and a slimming aid composition that promotes the obesity-improving action of the cannabidiol, wherein the slimming aid composition comprises: Since it is composed of an indigestible polymer compound and polyphenols, it is possible to provide an obesity-improving food containing a slimming aid composition that promotes the obesity-improving action of cannabidiol.
- cannabidiol when the cannabidiol is contained in 100 parts by weight of the food for ameliorating obesity at a ratio of 0.05 to 10 parts by weight, the obesity-improving action derived from cannabidiol can be enjoyed more steadily. .
- the indigestible polymer compound contains at least one selected from dextrin, starch, protein, and dietary fiber, only the indigestible polymer compound other than these is included in the slimming aid composition. Compared with the case where it is blended as an ingredient, the obesity-improving action can be promoted more remarkably.
- the indigestible polymer compound is contained at a ratio of 3 to 50 parts by weight in 100 parts by weight of the obesity-improving food, the obesity-improving action can be promoted more steadily.
- the polyphenols contain at least one selected from anthocyanin, ferulic acid, chlorogenic acid, catechin, and curcumin, when only polyphenols other than these are blended as components of the slimming aid composition , the obesity-improving action can be promoted more remarkably.
- the polyphenols are contained at a ratio of 1.5 to 20 parts by weight in 100 parts by weight of the obesity-improving food, the obesity-improving action can be promoted more steadily.
- the dosage form is powder, granules, granules, soft capsules, hard capsules, jelly, gummies, liquids or tablets, people from the young to the elderly can consume obesity-improving food in dosage forms suitable for their age. It can be carried out.
- FIG. 10 is an explanatory diagram showing the results of a confirmatory test of the promoting effect of the obesity-improving action of food A1 for improving obesity.
- FIG. 3 is an explanatory diagram showing the results of confirmation test of the promoting effect of amelioration of obesity when the content of cannabidiol is changed.
- FIG. 3 is an explanatory diagram showing the results of a confirmation test of the effect of promoting the obesity-improving action when the content of the indigestible polymer compound is changed.
- FIG. 4 is an explanatory diagram showing the results of a test to confirm the effect of promoting the obesity-improving action when the content of polyphenols is changed.
- the present invention relates to an obesity-improving food, and particularly to an obesity-improving food containing cannabidiol and a slimming aid composition that promotes the obesity-improving action of the cannabidiol.
- CBD cannabidiol
- cannabidiol is a component obtained from the seeds and stems of mature cannabis (Cannabis sativa L.), it tends to be misunderstood in Japan from the perspective of the Cannabis Control Law and is avoided as a food component. rice field.
- cannabidiol is completely different from the so-called “marijuana and cannabis” that have stimulating effects as stipulated in the Cannabis Control Law.
- “Cannabis” as defined in the Cannabis Control Law means flower heads and leaves of annual cannabis plants, or compounds with 21 carbon atoms derived from them. A representative of such components is tetrahydrocannabinol (THC), which is the main component of marijuana.
- cannabidiol which is also used in the present invention, is a component that is completely different in structure and physiological action from tetrahydrocannabinol, and is a safe mature cannabis plant for industrial use that does not exhibit stimulant or psychoactive effects like marijuana.
- Polyphenolic structures obtained from seeds or stems.
- cannabidiol exerts various useful effects by acting on cannabidiol receptors throughout the body.
- cannabidiol has already been commercialized in Japan by being incorporated into cosmetics and processed foods.
- cannabidiol are specialized for the action of a single component of cannabidiol, and are not formulated from the synergistic viewpoint of the biological and physiological actions originally possessed by cannabidiol.
- cannabidiol promotes the physiological functions of living organisms, and when commercializing cannabidiol preparations, it is necessary to promote metabolism, adjust the synaptic potential of the biological nervous system, and promote brain nerve transmission.
- Prescription design that takes into account physiological metabolism promotion such as is important.
- cannabidiol is a component that has the function of promoting and adjusting biologically active functions, and has a so-called trigger action that acts on physiologically active substances such as metabolic enzymes, neurotransmission functions, metabolic functions, and hormones that exist in living organisms. It has a mechanism.
- cannabidiol in formulations aimed at improving obesity, cannabidiol cannot be expected to have the desired effect unless it acts on the cannabinoid receptors (CB1, CB2) scattered throughout the body.
- the obesity-improving food according to the present embodiment can promote the obesity-improving effect of cannabidiol by blending cannabidiol with a slimming aid composition that promotes the obesity-improving effect of cannabidiol.
- a slimming aid composition that promotes the obesity-improving effect of cannabidiol.
- the slimming aid composition which is one of the characteristics of the food for improving obesity according to the present embodiment, is made up of an indigestible polymer compound and polyphenols. That is, the slimming aid composition can improve obesity as part of a daily diet because all constituent elements are food ingredients.
- cannabidiol be contained at a rate of 0.05 to 10 parts by weight in 100 parts by weight of food for improving obesity.
- cannabidiol By containing cannabidiol at such a concentration, the obesity improving effect derived from cannabidiol can be enjoyed more steadily.
- the indigestible polymer compound is a compound that has been recognized as safe when taken orally in an appropriate amount as food, and has the property of being difficult to be decomposed by digestive enzymes. Dextrin, starch, protein or dietary fiber are preferred.
- the indigestible polymer compound When the indigestible polymer compound is contained at a ratio of less than 3 parts by weight, it cannot sufficiently promote the obesity-improving action. Moreover, when it is contained at a rate exceeding 50 parts by weight, the obesity-improving action is not promoted in a concentration-dependent manner. Therefore, the indigestible polymer compound is desirably contained in a proportion of 3 to 50 parts by weight in 100 parts by weight of the food for improving obesity.
- polyphenols are recognized as safe when taken orally in appropriate amounts as food, and are compounds in which two or more hydrogen atoms of aromatic hydrocarbons are substituted with hydroxyl groups.
- it is a molecule having a plurality of phenolic hydroxyl groups or derivatives thereof, which are premised on safety in oral intake as described above, and is preferably anthocyanin, ferulic acid, chlorogenic acid, catechin, or curcumin.
- Comparative foods X1 to X3 were also prepared. Comparative foods X1 to X3 are manufactured by the same method as obesity-improving food A1, but lack some raw materials.
- the comparative food X1 is composed of 0.005 parts by weight of cannabidiol and 3.495 parts by weight of starch. It is a food that does not contain both ferulic acid and ferulic acid.
- Comparative food X2 is composed of 0.005 parts by weight of cannabidiol, 0.105 parts by weight of indigestible dextrin, and 3.390 parts by weight of starch. It is a food that does not contain the constituent ferulic acid.
- Comparative food X3 is composed of 0.005 parts by weight of cannabidiol, 0.053 parts by weight of ferulic acid, and 3.442 parts by weight of starch, and constitutes a slimming aid composition compared with food A1 for improving obesity.
- the food does not contain indigestible dextrin.
- Subjects were men and women in their 20s to 50s, 6 people (3 men, 3 women) in the group ingesting the obesity-improving food A1 (hereinafter referred to as the test group), and a group ingesting the comparative food X1 ( 6 persons (3 males, 3 females) in the first comparative group), and 6 persons (3 males, 3 females) in the group (hereinafter referred to as the second comparative group) ingesting food for comparison X2. 6 people (3 males and 3 females) in the group ingesting the comparative food X3 (hereinafter referred to as the 3rd comparison group), and 3 out of the 12 males and 12 females recruited. assigned randomly.
- comparative groups 1 to 3 are also collectively referred to as comparative groups.
- test group was asked to take 1 packet of obesity-improving food A1 30 minutes before dinner a day for 12 weeks.
- the control group was also allowed to ingest one of the corresponding food products X1 to X3 for 12 weeks, one packet per day 30 minutes before dinner.
- the subject in order for the subject to become accustomed to the environment in the test room under certain conditions (room temperature of 25 degrees, humidity of 50%), they first acclimatize for about 10 minutes. After acclimation, the subject stands barefoot on the measuring device and measures body fat according to the procedure of the measuring device.
- each person when taking measurements, each person should bring appropriate clothing (such as a T-shirt or shorts), weigh the clothing before wearing it, and use the weight measurement value that is the basis for calculating the body fat percentage. I decided to deduct it. During the test period, the subjects were instructed to refrain from overeating and drinking and to maintain a regular lifestyle. The results are shown in FIG.
- the second comparative group ingested the comparative food X2 containing cannabidiol and indigestible dextrin among the functional ingredients
- the third comparative group ingested the comparative food X3 containing cannabidiol and ferulic acid.
- a gradual decreasing trend was observed in changes in body fat percentage, almost the same as in Comparative Group 1.
- the slimming aid composition contained in the obesity-improving food A1 according to the present embodiment promotes the obesity-improving action of cannabidiol.
- Table 1 shows three types of foods with different cannabidiol contents.
- the obesity-improving food B1 has a cannabidiol content of 1.75 mg, which is equivalent to 0.05 parts by weight when the total weight of the food is 100 parts by weight, compared to the previous formulation of the obesity-improving food A1. , and the other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the obesity-improving food C1 has a cannabidiol content of 350 mg, which is equivalent to 10 parts by weight when the total weight of the food is 100 parts by weight, compared to the previous prescription of the obesity-improving food A1. , and other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the obesity-improving food C2 has a cannabidiol content of 525 mg, which is equivalent to 15 parts by weight when the total weight of the food is 100 parts by weight. , and other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the obesity-improving food D1 has an indigestible dextrin content of 50 parts by weight when the total weight of the food is 100 parts by weight, as compared with the formulation of the obesity-improving food A1. It is an obesity-improving food with a total weight of 1,750 mg and adjusted with starch while maintaining the same content of other functional ingredients.
- the obesity-improving food D2 has an indigestible dextrin content of 60 parts by weight when the total weight of the food is 100 parts by weight. It is an obesity-improving food with a weight of 2100 mg, with other functional ingredients having the same content and the total weight being adjusted with starch.
- the obesity-improving food D3 has a content of indigestible dextrin equivalent to 1 part by weight when the total weight of the food is 100 parts by weight. It is an obesity-improving food with a total weight of 35 mg and adjusted with starch while maintaining the same content of other functional ingredients.
- test method is the same as the above-mentioned "[1] Effect confirmation test with basic prescription", assigning 6 subjects, 3 men and 3 men, to each group, ingesting food for 12 weeks, each measurement Body fat percentage was measured daily. The results are shown in FIG.
- the body fat percentage increased in both the groups ingesting the obesity-improving food B1 and the obesity-improving foods D1 and D2.
- a significant decrease (p ⁇ 0.05) in the change in the weight loss is observed, and the indigestible polymer compound, indigestible dextrin, and the polyphenol, ferulic acid, act synergistically to function as a slimming aid composition.
- the obesity improving effect of cannabidiol was promoted.
- the obesity-improving food D3 which contains 35 mg of indigestible dextrin, which is equivalent to 1 part by weight when the total weight of the food is 100 parts, is the same as the comparative food X1, which contains only cannabidiol.
- each functional component did not act synergistically, and the function as a slimming aid composition was not exhibited. .
- the obesity-improving food F1 has a ferulic acid content of 700 mg, which is equivalent to 20 parts by weight when the total weight of the food is 100 parts by weight. , and other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the obesity-improving food F2 has a ferulic acid content of 1050 mg, which is equivalent to 30 parts by weight when the total weight of the food is 100 parts by weight, compared to the previous prescription of the obesity-improving food A1. , and other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the obesity-improving food F3 has a ferulic acid content of 35 mg, which is equivalent to 1 part by weight when the total weight of the food is 100 parts by weight, compared to the previous prescription of the obesity-improving food A1. , and other functional ingredients are the same, but the total weight is adjusted with starch to improve obesity.
- the body fat percentage increased in both the groups ingesting the obesity-improving food B1 and the obesity-improving foods F1 and F2.
- a significant decrease (p ⁇ 0.05) in the change in the weight loss is observed, and the indigestible polymer compound, indigestible dextrin, and the polyphenol, ferulic acid, act synergistically to function as a slimming aid composition.
- the obesity improving effect of cannabidiol was promoted.
- the content of ferulic acid is 35 mg, which is equivalent to 1 part by weight when the total weight of the food is 100 parts. This is a change in the body fat percentage, and as a result of the reduction in ferulic acid, each functional component did not act synergistically, and it was considered that the function as a slimming aid composition was not exhibited.
- the obesity-improving food contains cannabidiol and a slimming aid composition that promotes the obesity-improving action of the cannabidiol, Since the slimming aid composition comprises an indigestible polymer compound and polyphenols, it is possible to provide an obesity-improving food containing a slimming aid composition that promotes the obesity-improving action of cannabidiol. can.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
L'invention concerne un aliment améliorant l'obésité contenant une composition d'aide à l'amincissement qui favorise l'effet d'amélioration de l'obésité du cannabidiol. Cet aliment améliorant l'obésité contient du cannabidiol et une composition d'aide à l'amincissement qui favorise l'effet d'amélioration de l'obésité du cannabidiol, la composition d'aide à l'amincissement étant constituée d'un composé polymère non digestible et d'un polyphénol. Le cannabidiol est caractérisé en ce qu'il est inclus dans l'aliment d'amélioration de l'obésité selon un rapport de 0,05 à 10 parties en poids du cannabidiol pour 100 parties en poids de l'aliment améliorant l'obésité.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023553143A JPWO2023074707A1 (fr) | 2021-10-25 | 2022-10-25 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-174127 | 2021-10-25 | ||
JP2021174127 | 2021-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023074707A1 true WO2023074707A1 (fr) | 2023-05-04 |
Family
ID=86158013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/039801 WO2023074707A1 (fr) | 2021-10-25 | 2022-10-25 | Aliment améliorant l'obésité |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2023074707A1 (fr) |
WO (1) | WO2023074707A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190133966A1 (en) * | 2017-09-08 | 2019-05-09 | Scicann Therapeutics Inc. | Compositions comprising a cannabinoid and spilanthol |
US20210015762A1 (en) * | 2019-07-16 | 2021-01-21 | TRUETIVA, Inc. | Compositions for treating obesity |
JP2021090453A (ja) * | 2015-12-09 | 2021-06-17 | ポビバ コーポレーションPoviva Corp. | 脂溶性の活性物質を含む安定なレディ・トゥ・ドリンク飲料組成物 |
US20210251894A1 (en) * | 2019-01-04 | 2021-08-19 | Nutrition Therapeutics, Inc. | Functional beverage compositions and methods of using and making same |
WO2022024096A1 (fr) * | 2020-07-31 | 2022-02-03 | Ai Pharmaceuticals Jamaica Limited | Compositions et procédés pour favoriser la perte de poids et pour le traitement de l'obésité |
-
2022
- 2022-10-25 JP JP2023553143A patent/JPWO2023074707A1/ja active Pending
- 2022-10-25 WO PCT/JP2022/039801 patent/WO2023074707A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021090453A (ja) * | 2015-12-09 | 2021-06-17 | ポビバ コーポレーションPoviva Corp. | 脂溶性の活性物質を含む安定なレディ・トゥ・ドリンク飲料組成物 |
US20190133966A1 (en) * | 2017-09-08 | 2019-05-09 | Scicann Therapeutics Inc. | Compositions comprising a cannabinoid and spilanthol |
US20210251894A1 (en) * | 2019-01-04 | 2021-08-19 | Nutrition Therapeutics, Inc. | Functional beverage compositions and methods of using and making same |
US20210015762A1 (en) * | 2019-07-16 | 2021-01-21 | TRUETIVA, Inc. | Compositions for treating obesity |
WO2022024096A1 (fr) * | 2020-07-31 | 2022-02-03 | Ai Pharmaceuticals Jamaica Limited | Compositions et procédés pour favoriser la perte de poids et pour le traitement de l'obésité |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023074707A1 (fr) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oben et al. | The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study | |
Di Pierro et al. | GreenSelect (R) phytosome as an adjunct to a low-calorie diet for treatment of obesity: a clinical trial | |
Büyükbalci et al. | Determination of in vitro antidiabetic effects, antioxidant activities and phenol contents of some herbal teas | |
Hill et al. | Can EGCG reduce abdominal fat in obese subjects? | |
US20060280815A1 (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
JP2007508329A (ja) | 体重減少用サプリメント | |
JP7011885B2 (ja) | 腸の健康を促す組成物 | |
JP2008094754A (ja) | 糖尿病または血糖コントロール用栄養組成物 | |
JP2007513868A (ja) | サイトカインモジュレータ及び関係する使用法 | |
US20050277657A1 (en) | Method of protection of biologically active essential oils and pharmaceutical composition for weight control and enhance fat burning in adults, adolescents and children | |
Shari et al. | Hypolipidemic and Antioxidant Effects of Fenugreek-Nigella Sativa Combination on Diabetic Patients in Iraq. | |
AU2006347122B2 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus Acacia | |
WO2023074707A1 (fr) | Aliment améliorant l'obésité | |
JPWO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
US20070298136A1 (en) | Cholesterol regulating agent | |
WO2023074708A1 (fr) | Produit alimentaire pour améliorer l'endormissement | |
US8241682B2 (en) | Effects of Dichrostachys glomerata DG, Hypodaphnis zenkeri HZ, and Xylopia aethiopica XA on various cardiovascular risk factors and metabolic syndrome | |
US20120301573A1 (en) | Composition and method for suppressing appetite | |
Jenkins et al. | Herbal Infusions and Women’s Health: A Review of Findings with a Focus on Human Studies on Specific Infusions with Studies on Extracts to Evaluate Mechanisms | |
US6599522B2 (en) | Triglyceride reducing agent | |
CA2596200A1 (fr) | Produit a base d'herbes medicinales comprenant de la cannelle et du cafe | |
Majeed et al. | A new class of phytonutrients for body weight management | |
JP3195555U (ja) | ブルーベリー種を含有する視機能改善効果を有する機能性食品、及び錠剤又はカプセル錠剤。 | |
WO2021133950A1 (fr) | Compositions de polyphénol et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22887033 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023553143 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |